[go: up one dir, main page]

AR108377A1 - BISPECIFIC UNION PROTEINS AND ITS USES - Google Patents

BISPECIFIC UNION PROTEINS AND ITS USES

Info

Publication number
AR108377A1
AR108377A1 ARP170101161A ARP170101161A AR108377A1 AR 108377 A1 AR108377 A1 AR 108377A1 AR P170101161 A ARP170101161 A AR P170101161A AR P170101161 A ARP170101161 A AR P170101161A AR 108377 A1 AR108377 A1 AR 108377A1
Authority
AR
Argentina
Prior art keywords
seq
cdr1
cdr2
cdr3
binds
Prior art date
Application number
ARP170101161A
Other languages
Spanish (es)
Inventor
Jonathan Seaman
Prakash Manikwar
Brian Lobo
Scott A Hammond
Michael Oberst
Yariv Mazor
Kristen Pollizzi
Gianluca Carlesso
Darren Schofield
Stacey Drabic
Claire Louise Dobson
Michelle Morrow
Godfrey Rainey
Changshou Gao
Srinath Kasturirangan
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of AR108377A1 publication Critical patent/AR108377A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una proteína, caracterizada porque comprende un primer dominio de unión (BD1) que se une a un primer epitope, un segundo dominio de unión (BD2) que se une a un segundo epitope y una región Fc que comprende los dominios CH2 y CH3; en donde la región Fc comprende un BD2 en un bucle expuesto al solvente en el dominio CH2, el dominio CH3 o en la interfase de los dominios CH2 y CH3; y en donde la proteína es bivalente para la unión a cada uno entre el primer y el segundo epitopes. Reivindicación 38: Una proteína de unión biespecífica que se une a PD-1 y CTLA-4, caracterizada porque comprende un primer péptido que comprende la secuencia de aminoácidos de la SEQ ID Nº 5 y un segundo péptido que comprende la secuencia de aminoácidos de la SEQ ID Nº 6. Reivindicación 49: Un anticuerpo, o un fragmento de unión al antígeno del mismo, que se une a TIM3, caracterizado porque comprende una cadena pesada que comprende CDR1, CDR2 y CDR3 y una cadena liviana que comprende CDR1, CDR2 y CDR3, en donde la CDR1 de la cadena pesada comprende la SEQ ID Nº 79, la CDR2 de la cadena pesada comprende la SEQ ID Nº 80, la CDR3 de la cadena pesada comprende la SEQ ID Nº 81 y la CDR1 de la cadena liviana comprende la SEQ ID Nº 82, la CDR2 de la cadena liviana comprende la SEQ ID Nº 83, la CDR3 de la cadena liviana comprende la SEQ ID Nº 84. Reivindicación 56: Un método de tratamiento o prevención de un cáncer en un sujeto, caracterizado porque dicho método comprende administrar la proteína o el anticuerpo de cualquiera de las reivindicaciones 1 - 51 al sujeto.Claim 1: A protein, characterized in that it comprises a first binding domain (BD1) that binds to a first epitope, a second binding domain (BD2) that binds to a second epitope and an Fc region comprising the CH2 domains and CH3; wherein the Fc region comprises a BD2 in a loop exposed to the solvent in the CH2 domain, the CH3 domain or at the interface of the CH2 and CH3 domains; and where the protein is bivalent for binding to each other between the first and second epitopes. Claim 38: A bispecific binding protein that binds to PD-1 and CTLA-4, characterized in that it comprises a first peptide comprising the amino acid sequence of SEQ ID No. 5 and a second peptide comprising the amino acid sequence of the SEQ ID No. 6. Claim 49: An antibody, or an antigen binding fragment thereof, that binds to TIM3, characterized in that it comprises a heavy chain comprising CDR1, CDR2 and CDR3 and a light chain comprising CDR1, CDR2 and CDR3, wherein the CDR1 of the heavy chain comprises SEQ ID No. 79, the CDR2 of the heavy chain comprises SEQ ID No. 80, the CDR3 of the heavy chain comprises SEQ ID No. 81 and the CDR1 of the light chain comprises SEQ ID No. 82, CDR2 of the light chain comprises SEQ ID No. 83, CDR3 of the light chain comprises SEQ ID No. 84. Claim 56: A method of treating or preventing a cancer in a subject, characterized in that said method buy of administering the protein or antibody of any of claims 1-51 to the subject.

ARP170101161A 2016-05-06 2017-05-04 BISPECIFIC UNION PROTEINS AND ITS USES AR108377A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662332788P 2016-05-06 2016-05-06

Publications (1)

Publication Number Publication Date
AR108377A1 true AR108377A1 (en) 2018-08-15

Family

ID=60203374

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101161A AR108377A1 (en) 2016-05-06 2017-05-04 BISPECIFIC UNION PROTEINS AND ITS USES

Country Status (19)

Country Link
US (5) US10457732B2 (en)
EP (1) EP3452089A4 (en)
JP (3) JP6952716B2 (en)
KR (3) KR102490183B1 (en)
CN (1) CN109152835B (en)
AR (1) AR108377A1 (en)
AU (3) AU2017260365B2 (en)
BR (1) BR112018072485A2 (en)
CA (1) CA3021995A1 (en)
CL (1) CL2018003136A1 (en)
CO (1) CO2018012415A2 (en)
IL (2) IL298286A (en)
MA (1) MA44885A (en)
MX (2) MX2018013548A (en)
RU (2) RU2022102446A (en)
SG (1) SG11201809089QA (en)
TW (3) TWI757290B (en)
WO (1) WO2017193032A2 (en)
ZA (1) ZA201808160B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847589B (en) 2015-04-01 2022-03-29 安奈普泰斯生物有限公司 Antibodies against T cell immunoglobulin and mucin protein 3(TIM-3)
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
AU2016365742A1 (en) 2015-12-07 2018-06-21 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
WO2017106061A1 (en) 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
AR108377A1 (en) 2016-05-06 2018-08-15 Medimmune Llc BISPECIFIC UNION PROTEINS AND ITS USES
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
AU2017281157B2 (en) 2016-06-20 2024-07-25 F-Star Therapeutics Limited LAG -3 binding members
IL311603A (en) 2016-09-23 2024-05-01 Merus Nv Binding molecules that modulate a biological activity expressed by a cell
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
AU2018205401B2 (en) 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
AU2018221731C1 (en) 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
CA3078849A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against pd-l1
TWI742336B (en) * 2017-12-29 2021-10-11 圓祥生命科技股份有限公司 Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy, pharmaceutical composition, nucleic acid, and use thereof
EP3802613A4 (en) * 2018-06-05 2022-03-09 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Dimer and use thereof
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
JP7397055B2 (en) 2018-07-12 2023-12-12 エフ－スター セラピューティクス リミテッド Antibody molecules that bind to CD137 and OX40
CA3119161A1 (en) * 2018-11-13 2020-05-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
US20220185887A1 (en) * 2019-03-28 2022-06-16 Ab Studio Inc. Heteromultimeric proteins and methods of use thereof
TW202102539A (en) 2019-04-01 2021-01-16 美商伊梅塔斯科學療法公司 Binding protein, method for preparing the same, composition thereof, use thereof, nucleic acid molecule encoding the same and host cell comprising the nucleic acid molecule
CN110229232B (en) * 2019-06-19 2020-05-19 北京智仁美博生物科技有限公司 Bispecific antibodies and uses thereof
JP2022553176A (en) * 2019-10-17 2022-12-22 江蘇康寧杰瑞生物制薬有限公司 OX40/PD-L1 bispecific antibody
EP4069298A4 (en) * 2019-12-05 2024-01-03 Arbele Limited Composition of triaxial antibodies and method of making and using thereof
US20220204626A1 (en) * 2020-03-20 2022-06-30 Remegen Co., Ltd. Bispecific fusion protein and application thereof
MX2023004054A (en) 2020-10-07 2023-06-29 Dren Bio Inc Anti-dectin-1 antibodies and methods of use thereof.
CN114573704B (en) * 2021-03-10 2022-11-01 北京拓界生物医药科技有限公司 PD-1/CTLA-4 binding protein and medical application thereof
CN117120091A (en) * 2021-04-13 2023-11-24 免疫医疗有限责任公司 Bispecific antibodies targeting PD-1 and TIM-3
EP4326761A1 (en) * 2021-04-20 2024-02-28 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
WO2022223048A1 (en) 2021-04-23 2022-10-27 Suzhou Neologics Bioscience Co. , Ltd. Tim-3-targetting antibodies and uses thereof
TW202309086A (en) 2021-04-30 2023-03-01 美商麥迪紐有限責任公司 Bispecific pd-1 and tigit binding proteins and uses therof
AU2023231766A1 (en) * 2022-03-07 2024-10-17 Medimmune Llc Treatment methods using ctla-4 and pd-1 bispecific antibodies
AU2023313120A1 (en) 2022-07-28 2025-02-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
AU2023314375A1 (en) * 2022-07-28 2025-03-13 Medimmune, Llc Combination therapies for treatment of cancer
WO2024182781A1 (en) 2023-03-02 2024-09-06 Vir Biotechnology, Inc. Coronavirus compositions and uses thereof
WO2024216007A2 (en) * 2023-04-13 2024-10-17 Medimmune, Llc Pd-1/tigit binding proteins for cancer treatment
WO2024236529A1 (en) 2023-05-17 2024-11-21 Astrazeneca Ab Methods and combinations for treating cervical cancer
WO2024241246A1 (en) * 2023-05-23 2024-11-28 Medimmune, Llc PD-1/TIM-3 BINDING PROTEINS FOR TREATMENT OF NSCLC AND cHL

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
MX2008015524A (en) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function.
RS55229B1 (en) * 2009-12-29 2017-02-28 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
DK2794905T3 (en) * 2011-12-20 2020-07-06 Medimmune Llc MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY BASIC STRUCTURES
NZ729633A (en) * 2012-04-30 2019-03-29 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
TWI682941B (en) * 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
EP2832671B1 (en) 2013-07-30 2016-07-13 Hewlett-Packard Industrial Printing Ltd. Printing apparatus and methods
MX2016007965A (en) 2013-12-17 2016-10-28 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists.
CN103721255A (en) * 2014-01-07 2014-04-16 苏州大学 Application of co-blocking of PD-1 and TIM-3 signal paths to anti-stomach-cancer treatment
CA2936244A1 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
JOP20200094A1 (en) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody Molecules of PD-1 and Their Uses
JOP20200096A1 (en) * 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
CN104974253A (en) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 Anti-CTLA-4/PD-1 bispecific antibody as well as preparation method and application thereof
SG11201609468WA (en) 2014-05-29 2016-12-29 Medimmune Ltd Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
AU2015271100B2 (en) 2014-06-06 2020-07-30 Redwood Bioscience, Inc. Anti-HER2 antibody-maytansine conjugates and methods of use thereof
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TW201619200A (en) 2014-10-10 2016-06-01 麥迪紐有限責任公司 Humanized anti-OX40 antibodies and uses thereof
CA2964367C (en) * 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US10227411B2 (en) * 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN104987421A (en) * 2015-05-13 2015-10-21 北京比洋生物技术有限公司 Anti-CTLA-4 and PD-1 dual variable domain immunoglobulin
WO2017106061A1 (en) * 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
AR108377A1 (en) 2016-05-06 2018-08-15 Medimmune Llc BISPECIFIC UNION PROTEINS AND ITS USES

Also Published As

Publication number Publication date
EP3452089A4 (en) 2020-01-01
EP3452089A2 (en) 2019-03-13
JP2024045241A (en) 2024-04-02
US10457732B2 (en) 2019-10-29
MX2018013548A (en) 2019-05-20
AU2023208166A1 (en) 2023-10-12
USRE49908E1 (en) 2024-04-09
US11279759B2 (en) 2022-03-22
KR102490183B1 (en) 2023-01-20
SG11201809089QA (en) 2018-11-29
IL262437B2 (en) 2023-04-01
IL298286A (en) 2023-01-01
BR112018072485A2 (en) 2019-02-19
KR102674279B1 (en) 2024-06-12
WO2017193032A9 (en) 2018-02-22
TWI831124B (en) 2024-02-01
CO2018012415A2 (en) 2018-11-30
AU2017260365B2 (en) 2020-06-25
US20250074986A1 (en) 2025-03-06
US20200172622A1 (en) 2020-06-04
CL2018003136A1 (en) 2018-12-28
JP2022008601A (en) 2022-01-13
JP7171867B2 (en) 2022-11-15
CA3021995A1 (en) 2017-11-09
MA44885A (en) 2019-03-13
WO2017193032A3 (en) 2017-12-14
CN109152835A (en) 2019-01-04
AU2020204497B2 (en) 2023-04-27
CN109152835B (en) 2022-12-20
US20180022807A1 (en) 2018-01-25
KR20240096787A (en) 2024-06-26
TWI757290B (en) 2022-03-11
JP6952716B2 (en) 2021-10-20
AU2017260365A1 (en) 2018-12-20
WO2017193032A2 (en) 2017-11-09
RU2766199C2 (en) 2022-02-09
TW201741334A (en) 2017-12-01
MX2022015901A (en) 2023-01-24
RU2018142544A3 (en) 2021-02-09
IL262437B (en) 2022-12-01
KR20230013284A (en) 2023-01-26
RU2022102446A (en) 2022-03-10
ZA201808160B (en) 2021-08-25
JP2019520797A (en) 2019-07-25
US20220251204A1 (en) 2022-08-11
IL262437A (en) 2018-12-31
AU2020204497A1 (en) 2020-07-23
RU2018142544A (en) 2020-06-08
TW202222837A (en) 2022-06-16
TW202417514A (en) 2024-05-01
JP2023012528A (en) 2023-01-25
KR20190003963A (en) 2019-01-10

Similar Documents

Publication Publication Date Title
AR108377A1 (en) BISPECIFIC UNION PROTEINS AND ITS USES
CL2019001926A1 (en) Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017).
AR126019A1 (en) ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
PE20191463A1 (en) BISPECIFIC ANTIBODIES OF SPECIFIC JOINT PD1 AND LAG3
PE20221021A1 (en) ANTIGEN-BINDING PROTEINS THAT SPECIFICALLY BIND MAGE-A
AR111362A1 (en) ANTI-ILT4 ANTIBODIES AND ANTIGEN UNION FRAGMENTS
PE20240096A1 (en) BISPECIFIC ANTIBODIES SPECIFIC FOR A CO-STIMULATORY TNF RECEPTOR
PE20211291A1 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
CR20230169A (en) ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEM (divisional 2019-0485)
PE20131376A1 (en) ANTIBODIES TO MATRIX METALOPROTEINASE-9
PE20181046A1 (en) ANTI-TIGIT ANTIBODIES AND METHODS OF USE
PE20120475A1 (en) SPECIFIC ANTIBODIES FOR DKK-1
PE20231958A1 (en) BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF
PE20210552A1 (en) ANTI-TRANSTIRETIN ANTIBODIES
AR100680A1 (en) ANTI-DR5 ANTIBODIES AND MOLECULES THAT INCLUDE DR5 JOINT DOMAINS OF THE SAME
AR095115A1 (en) ANTIBODIES UNDERSTANDING CHEMICAL CONSTANT DOMAINS
PE20221262A1 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
MX2022000652A (en) Claudin18 antibodies and methods of treating cancer.
PE20180042A1 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM
PE20141908A1 (en) CD47 ANTIBODIES AND METHODS OF USE THEM
AR111830A1 (en) MONOCLONAL ANTI-BODIES ANTAGONISTS AGAINST CD40 AND ITS USES
PE20230408A1 (en) ANTI-LILRB1 ANTIBODY AND USES THEREOF
PE20220763A1 (en) MATERIALS AND METHODS FOR MODULATING T-CELL-MEDIATED IMMUNITY
JP2021502984A5 (en)
NI201800113A (en) HUMANIZED ANTI-BASIGIN ANTIBODIES AND THE USE OF THEM.